Rome

• TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of ARV-471 in Combination With Other Medicines in Adults With … Ended recruitment
  2022-502231-19-00 9 2024-01-02 ER+/HER2- Advanced or Metastatic Breast Cancer
• TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of Vepdegestrant (ARV-471) in Combination With Other Medicines … Ended recruitment
  2022-502228-34-00 9 2023-12-27 ER +/HER2- Advanced or Metastatic Breast Cancer
• Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322) Ended recruitment
  2022-502010-85-00 9 2023-12-20 Non-Squamous Non-Small Cell Lung Cancer
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm … Ended recruitment
  2023-505120-59-00 5 2023-12-19 Moderate to Severe Plaque Psoriasis
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended recruitment
  2022-502669-14-00 5 2023-12-18 Small cell lung cancer (SCLC)
• Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M … Ended recruitment
  2022-502975-45-00 5 2023-12-12 Metastatic leiomyosarcoma
• A Phase III multicenter study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients Ended recruitment
  2023-505160-12-00 5 2023-12-04 Essential Thrombocythaemia
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy … Ended recruitment
  2023-503309-13-00 5 2023-11-29 Moderate-to-Severe Thyroid Eye Disease
• A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or … Ended recruitment
  2023-509143-27-00 7 2023-11-27 Locally advanced or metastatic solid tumor malignancies, platinum resi
• Determine effectiveness of Anifrolumab In Systemic sclerosis Ended recruitment
  2023-505976-31-00 5 2023-11-24 Systemic Sclerosis (SSc) presenting with Limited or Diffuse Cutaneous
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended recruitment
  2023-503265-27-00 5 2023-11-23 Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
• A Phase 3, Open-label, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Chi … Ended recruitment
  2023-503294-37-00 5 2023-11-20 Osteogenesis Imperfecta
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended recruitment
  2023-503655-10-00 5 2023-11-20 Systemic Lupus Erythematosus (SLE).
• Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended recruitment
  2023-505023-31-00 5 2023-11-17 Renal cell carcinoma
• A Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephr … Ended recruitment
  2022-502102-32-00 5 2023-11-16 Primary Immunoglobulin A (IgA) Nephropathy
• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M … Ended recruitment
  2022-501863-41-00 5 2023-11-13 Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
• Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid-refractory acute graft versus host disease Ended recruitment
  2023-503952-28-00 4 2023-11-13 Steroid refractory Acute Graft versus host Disease
• Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy. DIAMOND STUDY Ended recruitment
  2024-518017-26-00 4 2023-11-07 metastatic HER2-positive breast cancer patients
• A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease. Ended recruitment
  2022-502789-26-01 4 2023-11-03 Fibrostenotic Crohn’s Disease
• A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N … Ended recruitment
  2022-500802-16-00 5 2023-11-01 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
• Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants with Multiple System Atrophy Ended recruitment
  2023-504876-12-00 5 2023-10-25 Neurogenic Orthostatic Hypotension
• A Study to Evaluate Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic He … Ended recruitment
  2023-503422-39-00 5 2023-10-20 Hepatocellular Carcinoma (HCC)
• A Phase 1/2 Study of BMS-986449 with and without Nivolumab in Participants with Solid Tumors Ended recruitment
  2023-503484-42-00 7 2023-10-19 Advanced, metastatic, solid malignancy
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD … Ended recruitment
  2022-501343-33-00 5 2023-10-18 Biochemically recurrent prostate cancer

Showing 1,273–1,296 of 2,096 trials